Cargando…

Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report

Detalles Bibliográficos
Autores principales:	Matsuda, Shogo, Yamamoto, Mahiro, Kotani, Takuya, Takeuchi, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor (Case report)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832225/ https://www.ncbi.nlm.nih.gov/pubmed/35155985 http://dx.doi.org/10.1093/rap/rkac003

Ejemplares similares

Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report. Reply
por: Matsuda, Shogo, et al.
Publicado: (2022)

Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis–interstitial lung disease: a case report
por: Sugimoto, Tomohiro, et al.
Publicado: (2022)

Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
por: Ho, Gen Nen, et al.
Publicado: (2023)

Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
por: Kotani, Takuya, et al.
Publicado: (2022)

The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease
por: Wakura, Reiko, et al.
Publicado: (2020)

Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis
por: Avouac, Jérôme, et al.
Publicado: (2013)

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies
por: Yanagihara, Toyoshi, et al.
Publicado: (2020)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Nailfold Capillaroscopic Changes as a Marker of Interstitial Lung Disease in Systemic Sclerosis: A Cross-Sectional Study in a Tertiary Care Hospital in Eastern India
por: Rudra, Olympia, et al.
Publicado: (2022)

Successful Treatment of Long-Term Severe Progressive Interstitial Pneumonia with Low-Dose Corticosteroid and Azathioprine in a Patient with Diffuse Systemic Sclerosis
por: Kotani, Takuya, et al.
Publicado: (2012)

Capillaroscopic pattern in inflammatory arthritis
por: Lambova, Sevdalina Nikolova, et al.
Publicado: (2012)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug
por: Kafle, Sunam, et al.
Publicado: (2021)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Efficacy and Safety of Nintedanib in Patients with Interstitial Lung Disease with or without Systemic Sclerosis: A Meta-Analysis
por: Lee, Young Ho, et al.
Publicado: (2023)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis
por: Suzuka, Takayasu, et al.
Publicado: (2022)

Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis
por: Shenavandeh, Saeedeh, et al.
Publicado: (2017)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Scleroderma-like capillaroscopic pattern in SLE is not a sign of overlap syndrome in both adults and children
por: Lambova, Sevdalina Nikolova
Publicado: (2022)

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
por: Campochiaro, Corrado, et al.
Publicado: (2023)

Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease
por: Matsuda, Shogo, et al.
Publicado: (2021)

Prevalence of retinal changes in patients with systemic sclerosis: the association between retinal vascular changes and nailfold capillaroscopic findings
por: Shenavandeh, Saeedeh, et al.
Publicado: (2021)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
por: Schmid, Ulrike, et al.
Publicado: (2021)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Capillaroscopic findings in Turkish Takayasu arteritis patients
por: AKDOĞAN, Ali, et al.
Publicado: (2019)

Capillaroscopic Evidence of Microvascular Damage in Volleyball Players
por: Sirufo, Maria Maddalena, et al.
Publicado: (2021)

Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings
por: Ferrari, Giorgia, et al.
Publicado: (2021)

Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis–associated interstitial lung disease mice
por: Mikami, Shintaro, et al.
Publicado: (2022)

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
por: Toellner, Hannah, et al.
Publicado: (2017)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7updhv0ar68a525i2coe76r55f